Trial Profile
Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jul 2014
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Chronic heart failure; Decompensated heart failure
- Focus Registrational; Therapeutic Use
- Acronyms REVIVE II study
- Sponsors Abbott Laboratories
- 26 Jul 2014 New trial record